(Q34172699)

31 July 2017

1 reference

title

Blocking the mTOR pathway: a drug discovery perspective (English)

1 reference

31 July 2017

1 reference

Carlos Garcia-Echeverria

series ordinal

1

1 reference

31 July 2017

publication date

1 April 2011

1 reference

Biochemical Society Transactions

31 July 2017

published in

1 reference

31 July 2017

volume

39

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

451-455

1 reference

Drug discovery approaches targeting the PI3K/Akt pathway in cancer

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

21 January 2018

Expanding mTOR signaling

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Raptor, a binding partner of target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

The role of mTOR in the management of solid tumors: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Von Hippel-Lindau disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Targeting the mTOR signaling network for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Targeting RAS and PI3K in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Class 1A PI3K regulates vessel integrity during development and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Drug-resistant phosphatidylinositol 3-kinase: guidance for the preemptive strike.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

The PTEN-PI3K pathway: of feedbacks and cross-talks

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST0390451

21 January 2018

Identifiers

DOI

10.1042/BST0390451

1 reference

31 July 2017

1 reference